Acorda Therapeutics, Inc. (ACOR) Director Barry E. Greene Sells 10,000 Shares
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Director Barry E. Greene sold 10,000 shares of Acorda Therapeutics stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $21.57, for a total transaction of $215,700.00. Following the sale, the director now owns 10,000 shares of the company’s stock, valued at approximately $215,700. The sale was disclosed in a document filed with the SEC, which is available through this link.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) traded down 1.494% during midday trading on Friday, hitting $21.425. 504,986 shares of the stock traded hands. The firm’s market cap is $984.33 million. Acorda Therapeutics, Inc. has a 12-month low of $13.60 and a 12-month high of $33.00. The company’s 50-day moving average is $19.98 and its 200 day moving average is $20.30.
Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.16. Acorda Therapeutics had a negative net margin of 8.02% and a negative return on equity of 6.37%. The business had revenue of $139.40 million during the quarter, compared to analyst estimates of $139.81 million. During the same quarter last year, the firm posted $0.07 earnings per share. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. On average, analysts anticipate that Acorda Therapeutics, Inc. will post $1.93 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Acorda Therapeutics, Inc. (ACOR) Director Barry E. Greene Sells 10,000 Shares” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/04/acorda-therapeutics-inc-acor-director-barry-e-greene-sells-10000-shares.html.
Several hedge funds and other institutional investors have recently bought and sold shares of ACOR. United Services Automobile Association acquired a new position in Acorda Therapeutics during the first quarter valued at approximately $8,946,000. Candriam Luxembourg S.C.A. raised its position in Acorda Therapeutics by 18.3% in the first quarter. Candriam Luxembourg S.C.A. now owns 71,000 shares of the biopharmaceutical company’s stock valued at $1,491,000 after buying an additional 11,000 shares during the last quarter. Great West Life Assurance Co. Can raised its position in Acorda Therapeutics by 10.2% in the first quarter. Great West Life Assurance Co. Can now owns 65,609 shares of the biopharmaceutical company’s stock valued at $1,374,000 after buying an additional 6,047 shares during the last quarter. Norges Bank acquired a new position in Acorda Therapeutics during the fourth quarter valued at approximately $8,128,000. Finally, Mason Street Advisors LLC raised its position in Acorda Therapeutics by 7.7% in the first quarter. Mason Street Advisors LLC now owns 10,852 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 775 shares during the last quarter.
A number of equities research analysts recently weighed in on the stock. BidaskClub lowered shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Stifel Nicolaus reiterated a “buy” rating on shares of Acorda Therapeutics in a report on Friday, July 28th. Jefferies Group LLC assumed coverage on shares of Acorda Therapeutics in a report on Monday, July 10th. They set a “hold” rating and a $22.00 price objective for the company. Zacks Investment Research lowered shares of Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 19th. Finally, TheStreet lowered shares of Acorda Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, April 24th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Acorda Therapeutics has a consensus rating of “Hold” and an average price target of $25.26.
About Acorda Therapeutics
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Stock Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related stocks with our FREE daily email newsletter.